| Title |
Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease
|
|---|---|
| Published in |
International Journal of Chronic Obstructive Pulmonary Disease, January 2016
|
| DOI | 10.2147/copd.s78000 |
| Pubmed ID | |
| Authors |
Maria Gabriella Matera, Alessandro Sanduzzi, Mario Cazzola |
| Abstract |
Co-administration of a long-acting β2-agonist and a long acting muscarinic antagonist produces superior bronchodilation compared with their individual effects. Our preclinical data indicated that combining aclidinium bromide (ACLI) and formoterol fumarate (FORM) provides synergistic benefit on smooth muscle relaxation of both large and small human airways. Data from more than 2,000 patients in eleven clinical trials documented that ACLI/FORM, a twice-daily fixed-dose combination, produces a greater degree of bronchodilation than ACLI or FORM monotherapy alone and is safe and well tolerated. Two large key trials have shown that there is a benefit in using ACLI/FORM when the clinical target is the variability of symptoms and mainly nighttime and/or early morning symptoms. ACLI/FORM is the only long acting muscarinic antagonist/long acting β2-agonist fixed-dose combination that has been studied for this therapeutic indication. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 22% |
| Brazil | 1 | 11% |
| Saudi Arabia | 1 | 11% |
| United States | 1 | 11% |
| Unknown | 4 | 44% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 67% |
| Science communicators (journalists, bloggers, editors) | 1 | 11% |
| Scientists | 1 | 11% |
| Practitioners (doctors, other healthcare professionals) | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 6% |
| Unknown | 15 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 5 | 31% |
| Student > Master | 4 | 25% |
| Student > Bachelor | 2 | 13% |
| Researcher | 2 | 13% |
| Professor | 1 | 6% |
| Other | 1 | 6% |
| Unknown | 1 | 6% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 50% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 25% |
| Chemistry | 1 | 6% |
| Economics, Econometrics and Finance | 1 | 6% |
| Unknown | 2 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 February 2016.
All research outputs
#6,872,007
of 25,718,113 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#760
of 2,593 outputs
Outputs of similar age
#98,539
of 401,646 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#18
of 55 outputs
Altmetric has tracked 25,718,113 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 2,593 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 401,646 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 55 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.